PanNASH Initiative

The #PanNASH Initiative aims to contribute to a better understanding and management of NASH, thus improving the lives of millions of patients worldwide

[PanNASH Initiative @PanNASH_Init]

Lanifibranor, the pan-PPAR agonist, shines in preclinical models of chronic #liverdisease—elevating #vascular function, reducing portal #hypertension & showcasing improvements in #hepatic #enzymes & #inflammation

#Lanifibranor #PPAR #LiverHealth

[PanNASH Initiative @PanNASH_Init]

Welcoming you into the new year with warm wishes for a blessed 2024 ahead! We look forward to continuously involving you in #PanNASH initiative, stay tuned for exciting updates. 🎇🎉

🖇️ https://t.co/acmB6eHjPu

#LiverTwitter

[PanNASH Initiative @PanNASH_Init]

NASH: The study employed #machinelearning with GBM to develop diagnostic models from histologically characterized data, identify patterns, & create predictive models that can be used in clinical trials & NASH biomarkers to help stratify at-risk patients.
🔗https://t.co/wmIlS5EotJ

[PanNASH Initiative @PanNASH_Init]

T1DM & #NAFLD present a intricate relationship that increases the risk of more severe MAFLD subtypes & vascular complications. This study investigates if two insulin administration modalities- MDI & CSII- are associated with MAFLD in adults with T1DM.

🔗https://t.co/yNHWihnpVo

[PanNASH Initiative @PanNASH_Init]

Did you know that higher levels of #alanine, #histidine, & #tyrosine have been linked to #NAFLD severity in both men & women, while different metabolic signatures were associated with the progression of the disease in men?

Read more - https://t.co/T2hKmEmEkB

#LiverTwitter

[PanNASH Initiative @PanNASH_Init]

NAFLD is a major global disease, affecting 1 in 3 adults & 10% of children/adolescents. This article aims to summarise the NAFLD-centred discussions & research priorities highlighted by experts during the International Precision Medicine Forum.

🔗https://t.co/d54UnyiNuz

[PanNASH Initiative @PanNASH_Init]

Transplant patients: 1/3 may develop obesity within a few years! Studies have shown that metabolic syndrome after transplantation may lead to MAFLD, a condition that causes graft dysfunction & fibrosis.

🖇️ https://t.co/Yh5B89ETmA

#LiverTwitter

[PanNASH Initiative @PanNASH_Init]

#CMS, a risk factor for #NAFLD, is a multi-faceted condition. Research is needed into biomarkers, treatments, & ethnic/socioeconomic/environmental factors to gain better understanding & develop more effective treatments.

🔗https://t.co/1IRynID9rW

#LiverTwitter

[PanNASH Initiative @PanNASH_Init]

💭Which non-invasive tool (#NIT) do you think shows the most promise in accurately detecting #liverfibrosis in #NAFLD patients with #T2DM?

Read more 👉 https://t.co/Q2ikPs5tnY

#livertwitter

[PanNASH Initiative @PanNASH_Init]

Quantifying mortality risks in #NAFLD: Insights from a meta-analysis. Learn how elevated liver stiffness measurements are linked to a higher risk of all-cause mortality.

Read more 👉 https://t.co/Of6Aqaer1X

#LiverFibrosis #HealthResearch #LiverTwitter

[PanNASH Initiative @PanNASH_Init]

🔬#NAFLD & pancreatic steatosis bidirectional relationship unveiled. A meta-analysis reveals significant associations & underscores the importance of understanding the liver-pancreas connection.
🔗 https://t.co/UZIaC7vd5l

#MedicalResearch #MetabolicHealth #Pancreas #LiverTwitter

[PanNASH Initiative @PanNASH_Init]

@VWSWong

[PanNASH Initiative @PanNASH_Init]

Key highlights from AASLD! Prof. Wong showcased the latest advances in #MASLD research.

#Lanifibranor, a pan-#PPAR agonist, with its potential to improve glucose levels. Dive into the discussion on advancements & side effects.

#LiverTwitter #NASH

[PanNASH Initiative @PanNASH_Init]

Dive into NAFLD diagnosis dynamics with Dr. Guillaume Grzych. Uncover the importance of diverse #biomarkers & interdisciplinary collaboration.

🔗 https://t.co/BO8Vx3LEze

#NAFLD #LiverHealth #Fibrosis

[PanNASH Initiative @PanNASH_Init]

Unveiling the ongoing global metabolic disease challenge: Insights from GBD data. #T2DM, #hypertension, #hyperlipidaemia, #obesity, & #NAFLD show increasing prevalence worldwide.

Learn more ➡️ https://t.co/C3MvSmCgIn

#LiverTwitter #LiverHealth

[PanNASH Initiative @PanNASH_Init]

🔬Enhancing #NASH trial success: Addressing comorbidities like #hypertension & #diabetes. Discover how addressing comorbid conditions like high blood pressure, #obesity, & type 2 diabetes can enhance the success of therapeutic trials.

Read more 👉https://t.co/AbhFvG6MiL

[PanNASH Initiative @PanNASH_Init]

Exploring #NASH treatment: Progress in targeting #inflammation & #fibrosis in Phase III trials. Learn about the agents paving the way to #liverhealth. https://t.co/oqzWBjWXPl

#LiverTwitter

[PanNASH Initiative @PanNASH_Init]

We are at #TLM23! Discussions highlight the evolving landscape with the new #nomenclature for #NASH = #MASLD. From fibrosis assessment to adolescent care, 8 KOLs are unraveling key questions.

#PanNASH #LiverHealth #TLMdX

[Vincent Wong @VWSWong]

#TLM2023 will start in 2 days! The @AASLDtweets MASLD SIG is pleased to share this MASLD program for your quick reference. See you in Boston soon!

[PanNASH Initiative @PanNASH_Init]

Nurturing healthy livers: Investigating #mitochondria 's critical role in #fattyliver disease progression. This study explores the nuanced variations in hepatic mitochondrial function across diverse fatty liver diseases.

🔗 https://t.co/oazjR7n8RV

#LiverTwitter